Of course that is your opinion .... I would expect nothing less than doom and gloom from a known MSB critic ... lol
You like many naysayers on here fail to acknowledge that the additional data from the 241 patients treated with Remestemcel-L through the FDA approved EAP will dramatically improve the BLA resubmission's chances .... you also fail to comprehend that the number 241 represents a figure far greater than any number of participants in any trial undertaken by Mesoblast for SR-aGVHD so one could form the view that Mesoblast have basically completed another trial anyway
banter and General Discussion, page-4777
-
- There are more pages in this discussion • 6,303 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |